X4 Pharmaceuticals Inc. (NASDAQ: XFOR) stock fell -7.34% on Monday to $1.01 against a previous-day closing price of $1.09. With 0.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.3 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.1200 whereas the lowest price it dropped to was $1.0100. The 52-week range on XFOR shows that it touched its highest point at $2.41 and its lowest point at $0.65 during that stretch. It currently has a 1-year price target of $4.79. Beta for the stock currently stands at 0.48.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XFOR was down-trending over the past week, with a drop of -16.53%, but this was up by 31.19% over a month. Three-month performance dropped to -45.11% while six-month performance fell -15.13%. The stock lost -46.84% in the past year, while it has gained 1.71% so far this year. A look at the trailing 12-month EPS for XFOR yields -2.82 with Next year EPS estimates of -0.83. For the next quarter, that number is -0.24. This implies an EPS growth rate of -28.80% for this year and 43.50% for next year.
Float and Shares Shorts:
At present, 83.21 million XFOR shares are outstanding with a float of 68.54 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.65 million, which was 2.40% higher than short shares on Sep 14, 2022. In addition to Dr. Paula Ragan Ph.D. as the firm’s Founder, CEO, Pres, Sec. & Director, Mr. Adam S. Mostafa serves as its CFO, Treasurer & Assistant Sec.
Through their ownership of 37.82% of XFOR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.09% of XFOR, in contrast to 15.22% held by mutual funds. Shares owned by individuals account for 1.38%. As the largest shareholder in XFOR with 5.12% of the stake, Empery Asset Management LP holds 6,198,684 shares worth 6,198,684. A second-largest stockholder of XFOR, AXA Investment Managers UK Ltd., holds 4,126,460 shares, controlling over 3.41% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in XFOR, holding 3,198,657 shares or 2.64% stake. With a 3.25% stake in XFOR, the AXA Framlington Biotech Fund is the largest stakeholder. A total of 3,929,336 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.40% of XFOR stock, is the second-largest Mutual Fund holder. It holds 2,903,141 shares valued at 2.88 million. FCP Medical – BioHealth holds 0.74% of the stake in XFOR, owning 900,034 shares worth 0.89 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XFOR since 8 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With XFOR analysts setting a high price target of $7.00 and a low target of $3.00, the average target price over the next 12 months is $4.79. Based on these targets, XFOR could surge 593.07% to reach the target high and rise by 197.03% to reach the target low. Reaching the average price target will result in a growth of 374.26% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. XFOR will report FY 2022 earnings on 03/14/2024. Analysts have provided yearly estimates in a range of -$1.26 being high and -$1.62 being low. For XFOR, this leads to a yearly average estimate of -$1.42. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. X4 Pharmaceuticals Inc. surprised analysts by $0.04 when it reported -$0.26 EPS against a consensus estimate of -$0.30. The surprise factor in the prior quarter was $0.03. Based on analyst estimates, the high estimate for the next quarter is -$0.18 and the low estimate is -$0.60. The average estimate for the next quarter is thus -$0.27.